Working in the field of drug development and human health by corroborating ancient medical concepts through modern methods, this pioneer in phytotechnology has a comprehensive new approach to finding novel plant-based therapeutics.
Atrimed Biotech was started in July 2016 by Dr. Latha Damle and her partners, set up with a vision to performing cutting edge combinatorial research in the fields of phytochemistry, bioinformatics and human immunology for therapeutic applications. The company has been incubated at the Bangalore Bioinnovation Centre, since early 2017.
Atrimed takes advantage of ancient wisdom such as that of Ayurveda, validating it through modern techniques. “Our products are all based on traditional knowledge adapted for the present, using cutting-edge technology”, says Dr. Latha Damle.
“Our mission is to be a premiere research organisation in the field of phyto-pharmaceuticals and develop new products for human healthcare”, says Dr. Latha Damle.
Atrimed’s work on developing low-cost, safe and topical medication for this condition can prove a boon to psoriasis patients.
The company focuses on high-quality Research and Development (R&D) and conducts pioneering work in the fields of phytochemistry and biotechnology. It partners with pharmaceutical companies to conduct research on ancient medical and healthcare concepts using modern-day techniques and methodologies, seeking to validate them for developing new and effective pharmaceutical products for therapeutic use and treatments.
Its research into plant-based therapeutics is geared towards developing products for different kinds of inflammation-driven skin diseases including acne and psoriasis – a chronic skin condition that affects around 100 million people worldwide. Expensive to treat, with each patient spending thousands of dollars on average, psoriasis has a high prevalence and in less developed countries, can also lead to social discrimination and in turn, financial losses for those afflicted by it. Atrimed’s work on developing low-cost, safe and topical medication for this condition can prove a boon to psoriasis patients.
Its innovative research model uses ‘in-silico’ platform in conjunction with other biotechnological methods and tools, that help test and validate different plant-based drug-like molecules. The platform is just as viable for research into therapeutics for other diseases and conditions including but not limited to hypertension, diabetes, and rheumatoid arthritis. The company has ongoing, comprehensive studies on diseases involving cancer immune checkpoints and antimicrobial resistance targets, among other aspects.
Atrimed has received funds from the Government of India and has also bagged research grants from the Government of Karnataka. In 2017, the company was awarded through ‘Elevate 100’ and received funding from Karnataka Biotechnology and Information Technology Services (KBITS) and the very next year, received the Biotechnology Ignition Grant (BIG) from India’s Biotechnology Industry Research Assistance Council (BIRAC).
Atrimed Biotech
